Top

Social Psychiatry and Psychiatric Epidemiology

Published in:

01-09-2017 | Original Paper

Homeless women with schizophrenia reported lower adherence to their medication than men: results from the French Housing First experience

Authors: A. Tinland, K. Zemmour, P. Auquier, M. Boucekine, V. Girard, S. Loubière, G. Fond, Laurent Boyer, French Housing First Study Group

Published in: Social Psychiatry and Psychiatric Epidemiology | Issue 9/2017

Abstract

Objective

The aim of this study was to investigate the factors associated with non-adherence to medication in a large multi-center sample of homeless schizophrenia (HSZ) patients.

Methods

This multi-center study was conducted in four French cities: Lille, Marseille, Paris, and Toulouse. In addition to the Medication Adherence Rating Scale (MARS), sociodemographic information, history of homelessness, illness severity using the Modified Colorado Symptom Index (MCSI) and the Multnomah Community Integration Scale (MCAS), and drug information were collected.

Results

In total, 218 HSZ patients (16.1% women, mean age 36.8 ± 9.3 years) were included in this study. In the multivariate analysis, being a woman and having higher illness severity (MCSI score) and lower “acceptance of illness” (MCAS score) were significantly associated with lower MARS index scores. Compared to men, women had lower MARS dimension 1 (‘medication adherence behavior’) and dimension 3 (‘negative side effects and attitudes toward psychotropic medication’) scores. First-generation antipsychotic use was also associated with lower MARS dimension 3 scores.

Conclusion

HSZ women reported lower adherence than men, mainly due to having more subjective negative side effects and worse attitudes toward psychotropic medication. Future longitudinal studies should confirm these findings and explore the applicability of specific pharmacological and non-pharmacological treatment strategies for HSZ women, including treatment dose adaptation and psychoeducation.

Clinical trial number NCT01570712.

Rezansoff SN, Moniruzzaman A, Fazel S, McCandless L, Procyshyn R, Somers JM (2016) Housing first improves adherence to antipsychotic medication among formerly homeless adults with schizophrenia: results of a randomized controlled trial. Schizophr Bull. doi:10.1093/schbul/sbw136 PubMedPubMedCentral

Fazel S, Geddes JR, Kushel M (2014) The health of homeless people in high-income countries: descriptive epidemiology, health consequences, and clinical and policy recommendations. Lancet 384(9953):1529–1540. doi:10.1016/S0140-6736(14)61132-6 CrossRefPubMedPubMedCentral

Folsom D, Jeste DV (2002) Schizophrenia in homeless persons: a systematic review of the literature. Acta Psychiatr Scand 105(6):404–413CrossRefPubMed

Auquier P, Tinland A, Fortanier C, Loundou A, Baumstarck K, Lancon C, Boyer L (2013) Toward meeting the needs of homeless people with schizophrenia: the validity of quality of life measurement. PLoS One 8(10):e79677. doi:10.1371/journal.pone.0079677 CrossRefPubMedPubMedCentral

Rezansoff SN, Moniruzzaman A, Fazel S, Procyshyn R, Somers JM (2016) Adherence to antipsychotic medication among homeless adults in Vancouver, Canada: a 15-year retrospective cohort study. Soc Psychiatry Psychiatr Epidemiol 51(12):1623–1632. doi:10.1007/s00127-016-1259-7 CrossRefPubMedPubMedCentral

Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW (2006) Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 67(3):453–460CrossRefPubMed

Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, Jeste DV (2004) Adherence to treatment with antipsychotic medication and health care costs among medicaid beneficiaries with schizophrenia. Am J Psychiatry 161(4):692–699. doi:10.1176/appi.ajp.161.4.692 CrossRefPubMed

Novick D, Haro JM, Suarez D, Perez V, Dittmann RW, Haddad PM (2010) Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res 176(2–3):109–113. doi:10.1016/j.psychres.2009.05.004 CrossRefPubMed

Sajatovic M, Levin J, Ramirez LF, Hahn DY, Tatsuoka C, Bialko CS, Cassidy KA, Fuentes-Casiano E, Williams TD (2013) Prospective trial of customized adherence enhancement plus long-acting injectable antipsychotic medication in homeless or recently homeless individuals with schizophrenia or schizoaffective disorder. J Clin Psychiatry 74(12):1249–1255. doi:10.4088/JCP.12m08331 CrossRefPubMedPubMedCentral

10.

Vollmer WM, Xu M, Feldstein A, Smith D, Waterbury A, Rand C (2012) Comparison of pharmacy-based measures of medication adherence. BMC Health Serv Res 12:155. doi:10.1186/1472-6963-12-155 CrossRefPubMedPubMedCentral

11.

Stirratt MJ, Dunbar-Jacob J, Crane HM, Simoni JM, Czajkowski S, Hilliard ME, Aikens JE, Hunter CM, Velligan DI, Huntley K, Ogedegbe G, Rand CS, Schron E, Nilsen WJ (2015) Self-report measures of medication adherence behavior: recommendations on optimal use. Transl Behav Med 5(4):470–482. doi:10.1007/s13142-015-0315-2 CrossRefPubMedPubMedCentral

12.

Somers JM, Moniruzzaman A, Currie L, Rezansoff SN, Russolillo A, Parpouchi M (2016) Accuracy of reported service use in a cohort of people who are chronically homeless and seriously mentally ill. BMC Psychiatry 16:41. doi:10.1186/s12888-016-0758-0 CrossRefPubMedPubMedCentral

13.

Fond G, Boyer L, Boucekine M, Aden LA, Schurhoff F, Tessier A, Andrianarisoa M, Berna F, Brunel L, Capdevielle D, Chereau I, Mallet J, Denizot H, Dorey JM, Dubertret C, Dubreucq J, Faget C, Gabayet F, Rey R, Richieri R, Passerieux C, Schandrin A, Urbach M, Vidailhet P, Llorca PM, Misdrahi D, group F-S (2016) Validation study of the Medication Adherence Rating Scale Results from the FACE-SZ national dataset. Schizophr Res. doi:10.1016/j.schres.2016.10.023

14.

Zemmour K, Tinland A, Boucekine M, Girard V, Loubiere S, Resseguier N, Fond G, Auquier P, Boyer L, French Housing First Study G (2016) Validation of the Medication Adherence Rating Scale in homeless patients with schizophrenia: results from the French Housing First experience. Sci Rep 6:31598. doi:10.1038/srep31598 CrossRefPubMedPubMedCentral

15.

Tinland A, Fortanier C, Girard V, Laval C, Videau B, Rhenter P, Greacen T, Falissard B, Apostolidis T, Lancon C, Boyer L, Auquier P (2013) Evaluation of the Housing First program in patients with severe mental disorders in France: study protocol for a randomized controlled trial. Trials 14:309. doi:10.1186/1745-6215-14-309 CrossRefPubMedPubMedCentral

16.

Ap A (2000) Diagnostic and statistical manual of mental disorders. Text revised, 4th edn. American Psychiatric Association, Washington, DC

17.

Jeste DV, Saks E (2006) Decisional capacity in mental illness and substance use disorders: empirical database and policy implications. Behav Sci Law 24:607–628CrossRefPubMed

18.

Girard V, Sarradon-Eck A, Payan N, Bonin JP, Perrot S, Vialars V, Boyer L, Tinland A, Simeoni MC (2012) The analysis of a mobile mental health outreach team activity: from psychiatric emergencies on the street to practice of hospitalization at home for homeless people. Presse Med 41(5):e226–e237. doi:10.1016/j.lpm.2011.09.032 CrossRefPubMed

19.

Conrad KJ, Yagelka JR, Matters MD, Rich AR, Williams V, Buchanan M (2001) Reliability and validity of a modified Colorado Symptom Index in a national homeless sample. Ment Health Serv Res 3(3):141–153CrossRefPubMed

20.

Barker S, Barron N, McFarland BH, Bigelow DA (1994) A community ability scale for chronically mentally ill consumers: Part I. Reliability and validity. Community Ment Health J 30(4):363–383CrossRefPubMed

21.

Barker S, Barron N, McFarland BH, Bigelow DA, Carnahan T (1994) A community ability scale for chronically mentally ill consumers: Part II. Applications. Community Ment Health J 30(5):459–472CrossRefPubMed

22.

Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20):22–33PubMed

23.

Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M (1993) Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption—II. Addiction 88(6):791–804CrossRefPubMed

24.

Misdrahi D, Tessier A, Swendsen J, Berna F, Brunel L, Capdevielle D, Chereau I, Danion JM, De Pradier M, Dorey JM, Dubertret C, Dubreucq J, Faget C, Gabayet F, Rey R, Richieri R, Passerieux C, Schandrin A, Schurhoff F, Tronche AM, Urbach M, Llorca PM, Fond G, Group F-S (2016) Determination of adherence profiles in schizophrenia using self-reported adherence: results from the FACE-SZ dataset. J Clin Psychiatry 77(9):e1130–e1136. doi:10.4088/JCP.15m10115 CrossRefPubMed

25.

Boyer L, Cermolacce M, Dassa D, Fernandez J, Boucekine M, Richieri R, Vaillant F, Dumas R, Auquier P, Lancon C (2012) Neurocognition, insight and medication nonadherence in schizophrenia: a structural equation modeling approach. PLoS One 7(10):e47655. doi:10.1371/journal.pone.0047655 CrossRefPubMedPubMedCentral

26.

Dassa D, Boyer L, Benoit M, Bourcet S, Raymondet P, Bottai T (2010) Factors associated with medication non-adherence in patients suffering from schizophrenia: a cross-sectional study in a universal coverage health-care system. Aust N Z J Psychiatry 44(10):921–928. doi:10.3109/00048674.2010.493503 CrossRefPubMed

27.

Goldberg JF, Ernst CL (2016) Core concepts involving adverse psychotropic drug effects: assessment, implications, and management. Psychiatr Clin North Am 39(3):375–389. doi:10.1016/j.psc.2016.04.001 CrossRefPubMed

28.

Ofotokun I, Pomeroy C (2003) Sex differences in adverse reactions to antiretroviral drugs. Top HIV Med 11(2):55–59PubMed

29.

El-Eraky H, Thomas SH (2003) Effects of sex on the pharmacokinetic and pharmacodynamic properties of quinidine. Br J Clin Pharmacol 56(2):198–204CrossRefPubMedPubMedCentral

30.

Faasse K, Petrie KJ (2013) The nocebo effect: patient expectations and medication side effects. Postgrad Med J 89(1055):540–546. doi:10.1136/postgradmedj-2012-131730 CrossRefPubMed

31.

Watson S (1986) Women and housing or feminist housing analysis? Hous Stud 1(1):1–10CrossRef

32.

Whitzman C (2010) Making the invisible visible: Canadian women, homelessness, and health outside the “big city”. In: Finding home: policy options for addressing homelessness in Canada. http://homelesshub.ca/sites/default/files/4.3%20Whitzman%20Homelessness%20Outside%20the%20Big%20City.pdf. Accessed 5 Jan 2017

33.

Sandercock L (1998) Making the invisible visible: a multicultural planning history. University of California Press, California, p 294

34.

Neale J (1997) Homelessness and theory reconsidered. Hous Stud 12(1):47–61CrossRef

35.

Tinland A, Boyer L, Loubière S, Greacen T, Girard V, Boucekine M, Fond G, Auquier P, Group FHFS (2017) Breaking women’s glass ceiling: violent victimization and post-traumatic stress disorder in homeless women with severe mental illnesses are associated with depression, suicide risk, impaired quality of life and impaired physical health. Results from the multisite French Housing First Study. Submitted

36.

Hui CL, Poon VW, Ko WT, Miao HY, Chang WC, Lee EH, Chan SK, Lin J, Chen EY (2016) Risk factors for antipsychotic medication non-adherence behaviors and attitudes in adult-onset psychosis. Schizophr Res 174(1–3):144–149. doi:10.1016/j.schres.2016.03.026 CrossRefPubMed

37.

Boyer L, Baumstarck K, Boucekine M, Blanc J, Lancon C, Auquier P (2013) Measuring quality of life in patients with schizophrenia: an overview. Expert Rev Pharmacoecon Outcomes Res 13(3):343–349. doi:10.1586/erp.13.15 CrossRefPubMed

38.

Velligan DI, Sajatovic M, Hatch A, Kramata P, Docherty JP (2017) Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Prefer Adherence 11:449–468. doi:10.2147/PPA.S124658 CrossRefPubMedPubMedCentral

39.

Caqueo-Urizar A, Boyer L, Baumstarck K, Gilman SE (2015) The relationships between patients’ and caregivers’ beliefs about the causes of schizophrenia and clinical outcomes in Latin American countries. Psychiatry Res 229(1–2):440–446. doi:10.1016/j.psychres.2015.06.033 CrossRefPubMedPubMedCentral

40.

Jonsdottir H, Opjordsmoen S, Birkenaes AB, Simonsen C, Engh JA, Ringen PA, Vaskinn A, Friis S, Sundet K, Andreassen OA (2013) Predictors of medication adherence in patients with schizophrenia and bipolar disorder. Acta Psychiatr Scand 127(1):23–33. doi:10.1111/j.1600-0447.2012.01911.x CrossRefPubMed

41.

Chan HY, Pan YJ, Chen JJ, Chen CH (2017) Time to discontinuation of second-generation antipsychotics versus haloperidol and sulpiride in people with schizophrenia: a naturalistic. Comparative study. J Clin Psychopharmacol 37(1):13–20. doi:10.1097/JCP.0000000000000623 CrossRefPubMed

42.

Chen VC, Liao YT, Lai TJ, Lane HY, Shao WC, Dewey M, Lee CT, Lu ML (2015) Survival analysis of the use of first and second generation antipsychotics among patients suffering schizophrenia: a nationwide population-based cohort study. Schizophr Res 169(1–3):406–411. doi:10.1016/j.schres.2015.10.005 CrossRefPubMed

43.

Karthik MS, Warikoo N, Chakrabarti S, Grover S, Kulhara P (2014) Attitudes towards antipsychotics among patients with schizophrenia on first- or second-generation medications. Indian J Psychol Med 36(3):288–293. doi:10.4103/0253-7176.135382 CrossRefPubMedPubMedCentral

44.

Warikoo N, Chakrabarti S, Grover S (2014) Adherence and continuation of treatment with first- and second-generation antipsychotics in schizophrenia. Indian J Psychol Med 36(1):33–39. doi:10.4103/0253-7176.127244 CrossRefPubMedPubMedCentral

45.

Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Moller HJ, Schizophrenia WTFoTGf (2015) World Federation of Societies of Biological Psychiatry (WFSBP). Guidelines for biological treatment of schizophrenia. Part 3: update 2015 management of special circumstances: depression, suicidality, substance use disorders and pregnancy and lactation. World J Biol Psychiatry 16(3):142–170. doi:10.3109/15622975.2015.1009163 CrossRefPubMed

46.

Newcomer JW (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19(Suppl 1):1–93PubMed

47.

Tschoner A, Engl J, Laimer M, Kaser S, Rettenbacher M, Fleischhacker WW, Patsch JR, Ebenbichler CF (2007) Metabolic side effects of antipsychotic medication. Int J Clin Pract 61(8):1356–1370. doi:10.1111/j.1742-1241.2007.01416.x CrossRefPubMed

48.

Caemmerer J, Correll CU, Maayan L (2012) Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trials. Schizophr Res 140(1–3):159–168. doi:10.1016/j.schres.2012.03.017 CrossRefPubMed

49.

Manu P, Dima L, Shulman M, Vancampfort D, De Hert M, Correll CU (2015) Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. Acta Psychiatr Scand 132(2):97–108. doi:10.1111/acps.12445 CrossRefPubMed

50.

Fialko L, Garety PA, Kuipers E, Dunn G, Bebbington PE, Fowler D, Freeman D (2008) A large-scale validation study of the Medication Adherence Rating Scale (MARS). Schizophr Res 100(1–3):53–59. doi:10.1016/j.schres.2007.10.029 CrossRefPubMed

51.

Velligan DI, Lam YW, Glahn DC, Barrett JA, Maples NJ, Ereshefsky L, Miller AL (2006) Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull 32(4):724–742. doi:10.1093/schbul/sbj075 CrossRefPubMedPubMedCentral

52.

Maremmani AG, Bacciardi S, Gehring ND, Cambioli L, Schutz C, Jang K, Krausz M (2017) Substance use among homeless individuals with schizophrenia and bipolar disorder. J Nerv Ment Dis 205(3):173–177. doi:10.1097/NMD.0000000000000462 CrossRefPubMed

53.

Verdoux H, Pambrun E, Tournier M, Bezin J, Pariente A (2017) Risk of discontinuation of antipsychotic long-acting injections vs. oral antipsychotics in real-life prescribing practice: a community-based study. Acta Psychiatr Scand 135(5):429–438. doi:10.1111/acps.12722 CrossRefPubMed

Title: Homeless women with schizophrenia reported lower adherence to their medication than men: results from the French Housing First experience
Authors: A. Tinland
K. Zemmour
P. Auquier
M. Boucekine
V. Girard
S. Loubière
G. Fond
Laurent Boyer
French Housing First Study Group
Publication date: 01-09-2017
Publisher: Springer Berlin Heidelberg
Published in: Social Psychiatry and Psychiatric Epidemiology / Issue 9/2017
Print ISSN: 0933-7954
Electronic ISSN: 1433-9285
DOI: https://doi.org/10.1007/s00127-017-1411-z

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Homeless women with schizophrenia reported lower adherence to their medication than men: results from the French Housing First experience

Abstract

Objective

Methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2017

Homotypic and heterotypic psychopathological continuity: a child cohort study

Internalizing and externalizing problems in childhood and adolescence as predictors of work incapacity in young adulthood

Suicide mortality among male veterans discharged from Veterans Health Administration acute psychiatric units from 2005 to 2010

Low emotion-oriented coping and informal help-seeking behaviour as major predictive factors for improvement in major depression at 5-year follow-up in the adult community

Systematic review of mental health disorders and intimate partner violence victimisation among military populations

Patterns of illness and care over the 5 years following onset of psychosis in different ethnic groups; the GAP-5 study